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Abstract 
The Rare Cancer Network (RCN), founded
in 1993, performs research involving rare
tumors that are not common enough to be the
focus of prospective study. Over 55 studies
have either been completed or are in progress. 
The aim of the paper is to present an
overview of the 30 studies done through the
RCN to date, organized by disease site. Five
studies focus on breast pathology, including
sarcoma, lymphoma, phyllodes tumor, adenoid
cystic carcinoma, and ductal carcinoma in situ
in young women. Three studies on prostate
cancer address prostatic small cell carcinoma
and adenocarcinoma of young and elderly
patients. Six studies on head and neck cancers
include orbital and intraocular lymphoma,
mucosal melanoma, pediatric nasopharyngeal
carcinoma, olfactory neuroblastoma, and
mucosa-associated lymphoid tissue lymphoma
of the salivary glands. There were 4 central
nervous system studies on patients with cere-
bellar glioblastoma multiforme, atypical and
malignant meningioma, spinal epidural lym-
phoma and myxopapillary ependymoma.
Outside of these disease sites, there is a wide
variety of other studies on tumors ranging
from uterine leiomyosarcoma to giant cell
tumors of the bone. The studies done by the
RCN represent a wide range of rare patholo-
gies that were previously only studied in small
series or case reports. With further growth of
the RCN and collaboration between members
our ability to analyze rare tumors will increase
and result in better understanding of their
behavior and ultimately help direct research
that may improve patient outcomes. 
Introduction
The Rare Cancer Network (RCN), which
was founded in 1993 by Professor René
Mirimanoff in Lausanne, started as an infor-
mal, well-organized group of radiation oncolo-
gists, from all over the world. The RCN was
made possible by the revolution in electronic
communication that occurred in the 1990’s.
Rapid communication through e-mail and a
dedicated web site (www.rarecancer.net) per-
mitted researchers across the globe to come
together in an informal network dedicated to
the study of rare cancers. 
The RCN has typically studied malignancies
that are too rare to the be the focus of prospec-
tive clinical trials. Although the results generat-
ed by RCN’s pooled studies reflect their retro-
spective and multi-institutional nature, with all
the biases that these limitations imply, they
may represent the highest level of evidence
available in the hierarchy of the evidence base,
nonetheless. 
Herein, we report a summary of the past
studies of the RCN that have undergone peer
review and publication.
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Figure 1. Location of Rare Cancer Network Primary Investigators in Europe, Asia (A) and
North America (B) for studies published 1993 to 2011.
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Materials and Methods
The Rare Cancer Network consists of 130
investigators in 24 countries (Supplemen-tary
Table 1). 
Membership is available for any clinical
investigator interesting in collaboration with
the network. Members can propose research
topics of rare cancers to the RCN coordinating
office to survey the rest of the membership for
level of interest. 
All studies undergo required review by ethics
or institutional review boards at each participat-
ing institution. Data is then extracted from
existing cases locally at each department accord-
ing to flow sheets designed by the primary inves-
tigator. This data is then pooled through elec-
tronic means for analysis. Authorship is a func-
tion of case contribution, with author rank
determined by the relative number of patients
contributed to each individual study.
The studies reported in this article were
identified from the RCN web site (www.
rarecancer.net) and through online searches
of PubMed. 
Results
Currently there are 55 studies either com-
pleted or in progress, including data from over
3500 patients, resulting in 28 peer reviewed
publications. The median study size was 81
(ranging from 9 to 443). All studies were multi-
center retrospective reviews. The studies
focused on rare cancers or rare presentations
of common cancers. The malignancies covered
were of a wide variety with fair distribution
among anatomic location and histology. Figure
1 illustrates the geographic location of study
primary investigators.
StudiesBreast
Five studies have focused on rare breast
pathologies as are outlined in Table 1.1,5
The cancer studies include breast sarcomas,
lymphoma, phyllodes tumor, ductal carcinoma in
situ (DCIS) in young women, and adenoid cystic
carcinoma. These were all multicenter, retro-
spective analyses with a median study size of
103 (range 61-443). Radiotherapy of some form
was found to be associated with an improved
outcomes in all breast studies except for the
Bousquet et al. sarcoma study, a study which
focused primarily on prognostic factors.1-5
Prostate
There have been three multi-center retro-
spective studies that have focused on prostate
cancers as outlined in Table 2.6-8
Two studies done by Nguyen et al. have
specifically addressed treatment of prostate
adenocarcinoma in the rare populations of
young (<55 years) and older (>80 years)
patients.6,7 For younger patients, the
researchers found that patients treated with
external beam radiotherapy had similar local
control rates as those undergoing radical
prostatectomy.6 For older patients, they found
no negative impact of curative radiotherapy on
disease free survival and overall survival, con-
cluding that radiotherapy in this group of eld-
erly patients with localized tumors was not
associated with increased toxicity or poort
tumor control rates.7
A third article by Stein et al. studied the
treatment of small cell carcinoma of the
prostate, concluding that the overall prognosis
of the disease was poor and combined modali-
ty therapy with cisplatin and radiotherapy was
not associated with improved outcomes, even
after a promising initial response in some
patients.8Head and neck
Six studies reviewed multi-center data for
several different head and neck cancers as
detailed in Table 3.9-14
Article
Table 1. Rare Cancer Network studies of breast cancers.
Breast Author Year Cases Results
Boost radiotherapy Omlin1 2006 373 Local relapse free survival at 10 years:
in young women 46% w/ no RT, 72% w/ RT no boost, 86% 
with DCIS w/ RT+boost
Outcome and Bousquet2 2007 103 5 year survival: disease free-44, over
prognostic factors all- 55%. favorable prognostic factors in
in breast sarcoma multivariate for LC: no residual tumor,
no cellular pleomorphism, and non
angiosarcoma histo. For DFS, non
menopausal status, no residual tumor
after tx, non-angio histo, absence of
tumor necrosis and lower grade
Phyllodes tumor Belkacemi3 2008 443 Benign tumors have good prognosis
of the breast after surgery alone. For malignant and
borderline group, RT decreased LR
and total mastectomy had better
results than conservational surgery
Management of Khanfir4 2011 61 For conservation group, RT improved
adenoid cystic 5-year LRC to 95% from 83%
carcinoma
of the breast
Primary breast lymphoma: Jeanneret- 2008 84 5yr survival: overall-53%, lymphoma
patient profile, outcome, Sozzi5 specific- 59%, disease-free 41%, local
prognostic factors control- 87%. Univariate analysis:
favorable prognostic factors- early
stage, conservative surgery, RT,
combined modality
Table 2. Rare Cancer Network studies of prostate cancer.
Prostate Author Year Cases Results
Curative role of Nguyen6 2005 39 Similar local control in younger and
radiotherapy in older patients from either EBRT
adenocarcinoma of the or radical prostatectomy
prostate in patients
under 55
Prostate cancer in Nguyen7 2009 65 No negative impact of radiation on
patients aged 80 or more disease free survival and global
survival
Small cell carcinoma Stein8 2008 30 Cisplatin+RT failed to improve
of the prostate: etiology, outcome after good initial response
diagnosis, prognosis, and
therapeutic implications
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This diverse group includes a pediatric
study analyzing nasopharyngeal carcinoma, a
rare disease for which an optimal treatment
has not been found.12 The study, the largest of
its kind, finds that patients had received com-
bined therapy with chemotherapy and radia-
tion had the longest survival. 
The study also found evidence suggesting
that a lower radiotherapy dose could be con-
sidered in patients with a good response to
chemotherapy, although no definitive conclu-
sions could be made given the retrospective
nature of the study. Anacak et al. reported the
largest series to date of patients with mucosa-
associated lymphoid tissue (MALT) lym-
phoma of the salivary glands.10 The
researchers found that patients treated with
radiotherapy were observed to have increased
disease-free survival. 
Treatment with both radiotherapy and sur-
gery was associated with an improved out-
come, both in a review of patients with olfacto-
ry neuroblastoma by Ozsahin.13 A similar rela-
tionship was found for mucosal melanoma
patients by Krengli and Mirimanoff.11Central nervous system
The RCN has completed four series on rare
cancers of the central nervous system
(Supplementary Table 2). 
A study by Weber on cerebellar glioblastoma
multiforme included 45 patients and found that
all patients had local progression.15 Pasquier et
al. reviewed 119 patients with atypical and
malignant meningiomas whom all received
radiotherapy and found 5 and 10-year survival
rates to be 65% and 51%, respectively.16
On univariate analysis, the authors found
survival was negatively affected by age >60,
poor performance status, and a high mitotic
rate. Fifty-two patients with spinal epidural
lymphomas were evaluated in a study by
Mirimanoff and were found to have good
response to chemoradiation versus radiation
alone.17
In patients with spinal myxopapillary
ependymoma, post-operative radiotherapy had
a significant increase in 5-year progression
free survival (82%) when compared to surgery
alone (50%).18Other
There are various other studies done by the
RCN as listed in Table 4.19-30
These studies vary from thyroid lymphomas
to uterine papillary sarcomas (Supplementary
Table 3). 
Discussion
Rare cancers present a challenge to the sci-
entific investigator.31 Their rarity typically pre-
vents the conduct of adequately powered clini-
cal trials or definitive study by any single indi-
vidual or institution. Multi-institutional efforts
can increase the volume of clinical data avail-
able for rare cancer studies, but such efforts
must compete with more common malignant
entities for funding. 
Although studying rare cancers through
prospective clinical trials is possible, as evi-
denced by the work of the Children’s Oncology
Group, most adult rare cancers have not been
the focus of a therapeutic clinical trial. 
Population based registries such as the
Surveillance Epidemiology and End Results
database (www.seer.cancer.gov) can provide
descriptive data on prevalence and outcomes,
but they are not designed to address specific
treatment related hypotheses in the manner of
clinical trials. Continued evolution of health
care informatics and population based care
delivery may provide increasing levels of out-
comes data on rare malignancies. 
Recently, the International Rare Cancer
Initiative was formed through a collaboration
of EORTC, Cancer Research UK, the National
Institute for Health Research Cancer Research
Network (NCRN), and the United States
National Cancer Institute (NCI). This organi-
zation will focus on designing clinical trials of
treatments for rare cancers and should
improve upon the quality of evidence in the
future. By pooling resources and patient
cohorts internationally through the infrastruc-
ture of existing national cancer research pro-
grams, it will provide valuable prospective data
on a limited number of rare tumor entities
such as small bowel cancer, rare head and neck
cancers, gynecological sarcoma, fibromellar
hepatocellular carcinomas, and penile carcino-
ma. (https://wiki.nci.nih.gov/display/ICWG/US-
UK-EORTC+Rare+Cancer+Initiative).
Additionally, patient advocacy organization
such as the National Organization for Rare
Disorders (www.rarediseases.org/) and Rare
Disease Europe (www.eurordis.org/) aid in the
fight against rare malignancies. 
The Rare Cancer Network was founded in
1993 to provide a multi-institutional frame-
work to facilitate rare cancer research, with a
focus on the specific role of radiation therapy,
through pooled data analysis by participating
academic medical centers across the world. 
In the last 19 years, the RCN has studied
many different rare cancers that previously
only had small series or case reports. With
pooling of data from around the world, the net-
work was able to produce a number of studies
for which meaningful clinical data is lacking
Article
Table 3. Rare Cancer Network studies of head and neck cancers.
Head and neck Author Year Cases Results
Outcome and prognostic Martinet9 2003 90 Moderate to low-dose RT (<34 Gy)
factors in orbital alone controls primary orbital
lymphoma lymphoma with low morbidity
Abstract: Outcomes and Mak10 2007 20 5-year overall, disease free survival,
prognostic factors in and local control rates of 55,39,72%.
primary intraocular high rate of CNS recurrence (51% at
lymphoma 5-years). Vitreous involvement=worse
prognosis. CNS prophylaxis and more
aggressive therapies need to be
considered
Radiotherapy in the Mirimanoff11 2006 74 Local control at 3 years- 57% with
treatment of mucosal surgery and 71% after surgery and RT
melanoma of the upper
aerodisgestive tract
Treatment results of 165 Ozyar12 2006 165 5-year overall survival 77.4%, disease
pediatric patients with free-68.8%. Combined RT and
non-metastatic chemotherapy was optimal treatment
nasopharyngeal
carcinoma
Outcome and prognostic Ozsahin13 2010 77 5 year survival: overall- 64%, disease
factors in olfactory free- 57, locoregional-62, local 
neuroblastoma control- 70. Surgery and post-op RT
(>53Gy) had best outcome.
Concomitant chemo+/-higher dose RT
should be prospectively investigated
Primary mucosa- Anacak14 2010 63 5 year disease free, disease specific,
associated lymphoid and overall survival- 54.4,93.2,81.7%. 
tissue lymphoma of the Recurrences may occur in up to 35%
salivary glands of patients at 5 years, survival not
affected. RT only modality that
improved disease- free survival
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on treatment outcomes. 
Although such studies cannot rank with ran-
domized controlled trials in terms of impact,
they do fill an important niche in between
anecdotal evidence and clinical trials in situa-
tions where a tumor’s rarity prevents prospec-
tive study. 
The multicenter and retrospective nature of
the studies can be seen as a significant limita-
tion on the conclusions of the studies due to
the variability of treatment, technique, and
population in different departments around
the world. However, as noted previously, for
many rare cancers, it would be difficult if not
impossible to study such tumors in a cost-effi-
cient fashion prospectively. The data and
results from the RCN studies serve to shed suf-
ficient light to advance the care for the unfor-
tunate patients that are diagnosed with these
rare diseases. 
With further collaboration and growing
members, the Rare Cancer Network can
improve upon not only the variety of data avail-
able to physicians on rare malignancies, but
also potentially outcomes for patients around
the world. 
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